Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include bisabolol, undecylenoyl phenylalanine and/or hexyldecanol, and a material selected from the group consisting of ethyl palmitate, stearyl alcohol, bis (2-ethylhexyl) adipate, bis (2-ethylhexyl) maleate, 5-pentadecanol, 1-stearoyl-rac-glycerol, bis (2-ethylhexyl) sebacate, and mixtures thereof. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.

Abstract: The invention relates to a process for relaxing keratin fibers by applying to the keratin fibers a relaxing composition containing at least one denaturing agent with a molecular mass of greater than 18.1 g/mol, present in a molar concentration of between 1M and 8M, and raising the temperature of the keratin fibers to a temperature of between 110 and 250° C.

Abstract: Disclosed is a cosmetic composition spread on lips to provide a color to lips. Disclosed are a lip pack cosmetic composition for tattooing and a method of preparing the same wherein lips are pigmented and thereby have tattoo effects by removing a formed layer after pigmenting a color on lips and drying the pigmented lips.

Abstract: Provided herein is an oral care composition comprising an orally-acceptable aqueous vehicle and an antimicrobial ingredient, wherein the antimicrobial ingredient comprises a zinc ascorbylphosphate and methods for treating or preventing a disease or disorder of the oral cavity using the oral care compositions disclosed herein.

Abstract: The present invention is related to a hair styling composition and process for styling keratin fibers, especially for hair. The object of the present invention is an aerosol composition for keratin fibers, especially for hair, based on an aqueous, aqueous-alcoholic or alcoholic medium comprising at least one natural starch and at least one propellant. Compositions according to present invention can furthermore comprise at least one film forming polymer, one or more surfactant, UV filter and direct hair dye.

Abstract: A liquid cosmetic which minimizes stickiness or stiffness caused by the incorporation of a large amount of a moisturizing agent is provided. This liquid cosmetic contains 10 to 40% by mass of a moisturizing agent (a), 0.01 to 3% by mass of an oil (b), 0.01 to 5% by mass of a hydrophilic surfactant (c), and 0.001 to 0.3% by mass polyacrylic acid or a metal salt thereof (d), and wherein an average emulsified particle size is 500 nm or smaller. Preferably, the amount of polyalkylene glycol contained in the moisturizing agent (a) is adjusted to 0.1 to 3 mass % relative to the whole cosmetic.

Abstract: The present invention provides a variable color transparent lip balm, consisting of following components by weight percent: 4.0 to 5.0% by weight of dibutyl lauroyl glutamide, 2.0 to 3.0% by weight of polyamide-3, 15.0 to 20.0% by weight of bis-stearyl ethylenediamine/neopentyl glycol/stearyl hydrogenated dimer dilinoleate copolymer, 46.65 to 49.60% by weight of C12-15 alkyl benzoate, 1.0 to 3.0% by weight of heptyl undecylenate, 9.0 to 11.0% by weight of C10-30 cholesterol/lanosterol esters, 10.0 to 15.0% by weight of hydrogenated C6-20 polyolefin, 1.5 to 2.5% by weight of dextrin isostearate, 0.05 to 0.1% by weight of eosin yellowish and 0 to 0.8% by weight of excipient. The transparent lip balm of the present invention has good transparency, and excellent variable color effect.

Abstract: Compositions comprising emu oil as a vehicle for the delivery of other active ingredients for the treatment of cosmetic and other skin imperfections such as acne, wrinkles, and hair loss are disclosed. Methods of treating cosmetic and other skin imperfections using the compositions are also disclosed.

Abstract: A method for protecting the skin against UV rays uses at least two cosmetic skincare and/or make-up compositions, and comprises applying a first layer of a first cosmetic composition comprising an oil phase and, optionally, an aqueous phase, followed by applying, on the first layer, a second layer of a second anhydrous composition comprising at least 70 wt.-% powders selected from among fillers and pigments, and an oil phase. At least one of the two compositions contains at least one UV filter, preferably a liposoluble UV filter. The first composition may be a make-up foundation or skincare base. The second composition may be a loose or compact powder.

Abstract: A hair rejuvenating lotion applied to a user's hair to treat and relieve symptoms caused by seborrheic dermatitis. Through use of plant extracts and other supplemental active ingredients, the hair rejuvenating lotion restores hair to a healthy condition, retains color and prevents hair loss. The plant extracts included are from the genera echinops, alchemilla, staphylea, and scorzonera, as well as the plants sophora japonica and nettle. The other supplemental active ingredients include sulfur, ammonium chloride, lead acetate, and castor oil. The base of the hair rejuvenating lotion consists of distilled water, glycerin, and ethyl alcohol. The plant extracts from the genera echinops, alchemilla, staphylea, scorzonera are dissolved into the ethyl alcohol to create a tincture solution. The tincture solution is mixed with the distilled water, glycerin, sulfur, sophora japonica extracts, nettle extracts, ammonium chloride, and castor oil to form the hair rejuvenating lotion.

Abstract: Methods of using extracts of Abutilon indicum to impart benefits to skin and/or improve skin conditions resulting from aging or damaged skin.

Abstract: The present invention relates to formulations of gelled lysozyme achieved by the addition of water to a lysozyme suspension in a solvent, such as an alcohol, with retention of enzymatic activity. It was surprisingly discovered that lysozyme itself is a gelling substance (self-gel) and, therefore, it can be advantageously formulated into topical compositions without the addition of other gelling substances such as cellulose, starch or other polysaccharides. The activity of the lysozyme is enhanced as compared to other formulations of comprising lysozyme. The formulations contained in the present invention are useful in methods in the fields of therapeutics, disinfectants, sanitizers, personal hygiene, and cosmetics for human and veterinary use.

Abstract: The invention relates to a solid or liquid pharmaceutical composition comprising botulinum neurotoxin complex (type A, B, C, D, E, F or G) or high purity botulinum neurotoxin (type A, B, C, D, E, F or G), and a surfactant. In particular the invention relates to a solid or liquid pharmaceutical composition comprising a crystalline agent.

Abstract: The disclosure provides a recipe for in-situ gel, formed by dissolving at least one polymer and at least one gel prevention agent in a polar solvent to form a solution and placing the solution in a condition for in-situ forming gels. The disclosure also provides an implant and a drug delivery system formed by the recipe.

Abstract: Stable solid compositions have a first carrier and an adsorbate having at least one active component, such as, a vitamin D derivative and a hydrophobic stabilizer thereof, wherein the first carrier is a calcium phosphate or derivatives thereof having a solubility in water lower than 0.1 wt % at room temperature.

Abstract: This invention relates to a gel-like composition in which ubiquinol is dispersed and stabilized in a gel and which contains 0.2 to 5% by weight of ubiquinol, 5 to 15% by weight of gelatin, 55 to 80% by weight of carbohydrate and/or water-soluble dietary fiber, and 9 to 18% by weight of water, and further contains ascorbic acid and/or gallate type catechin.

Abstract: Methods for preparing all-aqueous emulsions, including stable emulsions or emulsions having high viscosity and/or ultra-low interfacial tension are described. The method includes mixing, combining, or contacting a first electrically charged phase containing a first solute (e.g., dispersed phase) with at least a second phase containing a second solute (e.g., continuous phase). The solutes are incompatible with each other. The electrostatic forces between the two phases induce the formation of droplets of a dispersed phase in a continuous phase. The dispersed and continuous phases contain oppositely charged molecules, such as surfactants or other macromolecules and colloids which stabilize the drops of the dispersed phase. Complex coacervation of the oppositely charged molecules or colloids at the interface of the two aqueous phases results in formation of a membrane or barrier which prevents coalescence or aggregation of the droplets.

Abstract: Provided are compositions and methods relating to hydrophobic agent loaded-micelle. The micelles comprise surfactant (such as poloxamer) and have hydrophobic agents incorporated therein. The compositions substantially lack surfactant that is not associated with the micelles. The compositions are able to achieve high hydrophobic agent: surfactant molar ratio. The compositions can be used for drug delivery and imaging applications.

Abstract: The present invention consists of a novel process for the incorporation of one or more water-soluble active agents in a hydrophilic polymer foam. Said process makes it possible in particular to obtain a hydrophilic polyurethane foam exhibiting a gradient of active agents. This process is of particular use when manufacturing hydrophilic polyurethane foams intended for medical, cosmetic and dermocosmetic purposes.

Abstract: The present invention generally relates to the field of pharmaceutical sciences. More specifically, the present invention includes apparatus and devices for the preparation of pharmaceutical formulations containing large diameter synthetic membrane vesicles, such as multivesicular liposomes, methods for preparing such formulations, and the use of specific formulations for therapeutic treatment of subjects in need thereof. Formation and use of the pharmaceutical formulations containing large diameter synthetic membrane vesicles produced by using the apparatus and devices for therapeutic treatment of subjects in need thereof is also contemplated.

Abstract: The present invention relates to novel multicompartmental lipid nanoparticles (or cellisomes) with excellent stability comprising a first lipophilic compartment (lipid matrix) partly anchored to a second hydrophilic compartment delimited by a phospholipid bilayer (bilayer), as well as the method for preparing same and the use thereof as a vector for administering a wide variety of molecules of interest.

Abstract: A sustained-release formulation for an acetylcholinesterase inhibitor, comprising an acetylcholinesterase inhibitor and at least two gel-forming polymers, and methods of manufacture thereof. The acetylcholinesterase inhibitor preferably comprises donepezil.

Abstract: The present invention contemplates induction of immunological tolerance thereby providing permanent allograft acceptance. This method obviates the need for a lifelong regimen of immunosuppressive agents which can increase the risk of infection, autoimmunity, and cancer. Immunological tolerance is thought to be mediated by regulatory T lymphocytes (Treg cells) with immunosuppressive capabilities. A therapeutically relevant platform comprising artificial constructs are contemplated comprising numerous soluble and surface bound Treg cell stimulating factors that may induce tolerance following allograft transplantation. Such artificial constructs, being the size of a cell, have surface bound monoclonal antibodies specific to regulatory T-cell surface moieties and encapsulated soluble regulatory T-cell modulating factors.

Abstract: The present invention relates to pharmaceutical compositions intended to be used in the form of a solid unit such as a tablet, for oral administration, comprising a high content of fexofenadine and/or of at least one pharmaceutically acceptable salt thereof, and also to hot-melt processes for manufacturing solid units.

Abstract: Disclosed in certain embodiments is a controlled release oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse together with one or more pharmaceutically acceptable excipients; the dosage form further including a gelling agent in an effective amount to impart a viscosity unsuitable for administration selected from the group consisting of parenteral and nasal administration to a solubilized mixture formed when the dosage form is crushed and mixed with from about 0.5 to about 10 ml of an aqueous liquid; the dosage form providing a therapeutic effect for at least about 12 hours when orally administered to a human patient.

Abstract: The present invention relates to a method for preparing a protein cage which comprises: a 1st step of preparing an amphiphilic polymer comprising a 1st hydrophobic polymer and a 1st hydrophilic functional group; a 2nd step of preparing a hydrophilic protein comprising a 2nd functional group binding to the 1st functional group; a 3rd step of forming an amphiphilic polymer-protein hybrid by the binding of the 1st functional group and the 2nd functional group, and forming core-shell structured particles comprising a protein shell and an amphiphilic polymer core by the self-assembly of the amphiphilic polymer in a hydrophilic solvent; and a fourth step of removing some or all of the hydrophobic polymer of the core part from the core-shell structured particles.

Abstract: The invention relates to a pH-dependent controlled release pharmaceutical composition, comprising a core, and an opioid, wherein the core is coated at least by one coating layer, controlling the release of the pharmaceutical composition, wherein the coating layer comprises a polymer mixture of i) 40-95% by weight, based on dry weight of the polymer mixture, of at least one water insoluble essentially neutral vinyl polymer, and ii) 5-60% by weight, based on dry weight of the polymer mixture, of at least one anionic polymer or copolymer, which is insoluble in a buffered medium below pH 4.0 and soluble at least in the range from pH 7.0 to pH 8.0, characterized in that the coating layer further comprises 110 to 250% by weight of a non-porous inert lubricant, 1 to 35% by weight of a neutral cellulosic compound and 1 to 25% by weight of an emulsifier, each calculated on dry weight of the polymer mixture.

Abstract: A coated fine particle comprisisng: (i) a complex of a drug and a cationic lipid, wherein (a) the drug is a nucleic acid and the complex is obtained by mixing the drug and the cationic lipid in water, wherein the complex has a diameter of 10 nm to 1,000 nm, and (ii) a lipid layer formed of lipid(s), wherein the lipid(s) is selected from phospholipid, glyceroglycolipid, sphingoglycolipid, cholesterol and synthetic lipid, wherein the complex is coated with the lipid layer.

Abstract: Disclosed are nutritional compositions, and methods of using and making the nutritional compositions, that include calcium beta-hydroxy-beta-methylbutyrate and protein. The calcium beta-hydroxy-beta-methylbutyrate is in sequestered or ion-exchanged form to reduce the interaction of the calcium with the protein in the nutritional composition and improve the overall stability of the nutritional composition.

Abstract: The invention provides methods of treatment that induce satiety in a subject for a period of at least around twenty-four hours by once-daily administration to the subject of a controlled release dosage form, wherein the dosage form is administered while the subject is in the fasted state and at a time of around six to around nine hours prior to the subject's next intended meal, and wherein the dosage form comprises a controlled release composition, which comprises an enterically-coated, ileum hormone-stimulating amount of a nutritional substance and releases the majority of the nutritional substance in vivo upon reaching the subject's ileum. The invention also provides a diagnostic tool for probing the health and disease state of the ileal hormones, excess or deficiencies. The invention provides a safe vehicle for targeted deliveries of chemical, pharmaceuticals, natural substances and nutrition to the ileum.

Abstract: An ingestion method of creatine composition, taking orally the creatine composition with beverage, characterized in that, the creatine composition is taken orally by preparing creatine composition aqueous solution with dissolving the creatine composition over one minute into water heating at 80-100° C. and by mixing the creatine composition aqueous solution with the beverage having ordinary or cool temperature.

Abstract: The present invention provides methods, compositions, and kits for treating intestinal hyperpermeability in a subject in need thereof, including conditions such as hyperglycemia and underlying diseases such as diabetes, autism, fibromyalgia, inflammatory bowel disease (IBD), graft versus host disease (GVHD), HIV/AIDS, multiple organ dysfunction syndrome, irritable bowel syndrome (IBS), celiac disease, eczema, psoriasis, acute pancreatitis, Parkinson's disease, depression, chronic fatigue syndrome, asthma, multiple sclerosis, arthritis, ankylosing spondylitis, nonalcoholic fatty liver disease, alcoholic cirrhosis, environmental enteropathy, or kwashiorkor.

Abstract: Use of cilastatin to reduce the nephrotoxicity of different compounds. The invention refers to use of cilastatin to prepare a medicinal product to reduce the nephrotoxicity of a nephrotoxic compound that enters the cells of the proximal tubule through cholesterol rafts. The invention is based on the discovery that a great number of nephrotoxic compounds, including drugs, enter the cells of the proximal tubule through the cholesterol rafts, and that cilastatin is able to interfere with this transport mechanism, decreasing the nephrotoxicity of such compounds to a variable extent. The nephroprotective effect is common to compounds of different chemical nature and solubility and is specific for the kidney, causing no interference with the effects of nephrotoxic drugs having their targets in other organs. Therefore, administration of cilastatin allows for decreasing the nephrotoxic effects of different drugs without reducing their therapeutic effects.

Abstract: Replication protein A (RPA) is a single-strand DNA-binding protein with essential roles in DNA replication, recombination and repair. Small molecule inhibitors (SMIs) with the ability to disrupt RPA binding activity to ssDNA have been identified and assessed using both lung and ovarian cancer cell lines. Lung cancer cell lines demonstrated increased apoptotic cell death following treatment with the SMI MCI13E, with IC50 values of ˜5 ?M. The A2780 ovarian cancer cell line and the p53-null lung cancer cell line HI 299 were particularly sensitive to MCI13E treatment with IC50 values below 3 ?M. Sequential treatment with MCI13E and cisplatin resulted in synergism, suggesting that decreasing RPA's DNA binding activity via a SMI may disrupt RPA's role in cell cycle regulation. Thus, RPA SMIs hold the potential to be used as single agent chemotherapeutics or in combination with current chemotherapeutic regimens to increase their efficacy.

Abstract: The invention relates to a coated medical device for rapid delivery of a therapeutic agent to a tissue in seconds to minutes. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent, at least one of an oil, a fatty acid, and a lipid, and an additive. In certain embodiments, the additive has a hydrophilic part and a drug affinity part, wherein the drug affinity part is at least one of a hydrophobic part, a part that has an affinity to the therapeutic agent by hydrogen bonding, a part that has an affinity to the therapeutic agent by charge, and a part that has an affinity to the therapeutic agent by van der Waals interactions. In embodiments, the additive is at least one of a surfactant and a chemical compound. In further embodiments, the chemical compound is water-soluble.

Abstract: The present invention relates to a stable, sterile, ready to administer parenteral dosage form of amiodarone or its pharmaceutically acceptable salt. Particularly, the present invention provides a stable, sterile, ready to administer parenteral dosage form of amiodarone comprising an aqueous solution comprising amiodarone or its pharmaceutically acceptable salt, an acid, and a polyol, wherein the pH of the solution is in the range of about 2.0 to 4.0, wherein the solution is filled in a plastic container and wherein the solution is free of a solubilizer.

Abstract: Methods of inducing anesthesia in a subject by administering an effective amount of a compound or a mixture of compounds according to Formula I are provided. Compounds of Formula I are a class of halogenated alcohol derivatives with a vapor pressure of at least 0.1 atmospheres (76 mmHg) at 25° C. Compounds of Formula I can be administered by any route sufficient to achieve a desired anesthetic endpoint.

Abstract: The invention provides compositions and methods for treating cyanide poisoning.

Abstract: Provided herein are controlled release oral dosage forms of poorly soluble drugs, methods of making the dosage forms, and methods of their use for the treatment of various diseases and/or disorders.

Abstract: A pharmaceutical composition and a method for preventing or treating a cardiovascular disease are provided. The pharmaceutical composition includes a BIO compound ((2?Z,3?E)-6-bromoindirubin-3?-oxime) or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition can specifically act on different types of cells constituting heart tissues, that is, can induce the growth of cardiomyocytes, and can also inhibit proliferation of cardiac fibroblasts and strongly suppress inflammatory mediators in macrophages, thereby significantly recovering the tissues and functions of the heart after the onset of myocardial infarction. Therefore, the pharmaceutical composition can be effectively used to treat various cardiovascular diseases including myocardial infarction.

Abstract: It is intended to provide a therapeutic and/or diagnostic agent that can be used in photodynamic therapy (PDT) or photodynamic diagnosis (PDD) capable of utilizing infrared-spectrum light such as near-infrared light (NIR), infrared light, or far-infrared light, which attains a deep body penetration. The present invention provides a photodynamic therapeutic or diagnostic agent or a photodynamic therapeutic or diagnostic kit for cancer or infectious disease, comprising: a particle (e.g., a lanthanide particle) that emits upconversion luminescence by infrared-spectrum light such as near-infrared light having a wavelength of 0.7 ?m to 2.5 ?m; and a photosensitizer (e.g., porphyrin) or a 5-aminolevulinic acid group.

Abstract: The invention refers to a combination comprising a sigma ligand of formula (I) and an opioid or opiate for use in the prevention and/or treatment of pain developed as a consequence of surgery, especially peripheral neuropathic pain, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuralgia, neuritis or neuropathy. The invention also refers to the sigma ligands of formula (I) for use in potentiating the analgesic effect of an opioid or opiate and/or for decreasing the dependency induced thereby when said opioid or opiate is used in the prevention and/or treatment of pain developed as a consequence of surgery.

Abstract: The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.

Abstract: The invention relates to the use of pharmaceutical compositions containing as the active agent a compound of formula I in the treatment of dermal wounds. The compositions may be used for the promotion of healing of wounds affecting the deeper layers under the epithelium, including dermal- and sub dermal connective tissue, being cut, punctured, sliced wounds or originating in insufficient tissue perfusion, chronic diseases or other harms. The compositions are formulated for local application and may comprise other active agents contributing to wound healing in addition to a compound of formula (I).

Abstract: This invention concerns the use of cyclopamine, a naturally occurring steroidal alkaloid known for over thirty years, for the treatment of psoriasis and achievement of rapid clearance of the psoriatic skin lesions together with the reversion of the histopathological signs of disease to normalcy with no detectable side effects. The cyclopamine-induced clearance of psoriatic lesions from the skin of patients is associated with the causation of cellular differentiation in lesional epidermis and with the rapid disappearance of CD4(+) lymphocytes and other inflammatory cells from lesional skin. Therapeutic compositions comprising of cyclopamine and a corticosteroid and/or the pre-treatment of lesions with a corticosteroid provide significantly further increased therapeutic effectiveness over the use of cyclopamine alone or a corticosteroid alone.

Abstract: A modified release composition comprising tacrolimus releases less than 20% w/w of the active ingredient within 0.5 hours when subjected to an in vitro dissolution test using USP Paddle method and using 0.1 N HCl as dissolution medium and has increased bioavailability by effectively reducing or even avoiding the effects of CYP3A4 metabolism. The modified composition may be coated with an enteric coating; and/or may comprise a solid dispersion or a solid solution of tacrolimus in a hydrophilic or water-miscible vehicle and one or more modifying release agents; and/or may comprise a solid dispersion or a solid solution of tacrolimus in an amphiphilic or hydrophobic vehicle and optionally one or more modifying release agents.

Abstract: The present invention relates to SNS-595 and methods of treating cancer using the same.

Abstract: The invention relates to new naphthyridine derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.

Abstract: The present invention relates to a sterile pharmaceutical composition comprising tiotropium or a pharmaceutically acceptable salt thereof, for inhalation via nebulization to a subject (e.g. a human). The invention also relates to a process for preparing the pharmaceutical composition and its use in the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) in a subject.

Abstract: Methods for the treatment of Parkinson's disease psychosis which comprise the administration of pimavanserin.